investigating the treatment of unselected mcrpc patients with a cdk 4/6 inhibitor plus abemaciclib
Published 2 years ago • 125 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
4:54
monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
-
6:15
breast cancer at esmo 2020: cdk4/6 inhibitors and checkpoint inhibitors
-
2:31
cdk4/6 inhibitors: a hot topic in breast cancer treatment
-
1:04
biomarkers to help predict response to cdk4/6 inhibitors
-
3:53
upcoming advances in prostate cancer: parpi, cdk4/6, lutetium psma therapy & car-t approaches
-
4:35
hr breast cancer: differences between cdk4/6 inhibitors
-
2:07
remaining questions regarding the use of frontline cdk4/6 inhibitors and endocrine therapy
-
1:02:43
realizing the potential of cdk 4/6 inhibitor therapy in breast cancer: real-world data and evidence
-
1:39
challenges in the field of parpi treatment for mcrpc
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
7:59
what are cdk 4/6 inhibitors for breast cancer?
-
1:19
highlights in prostate cancer from esmo
-
3:38
mbc: cdk4/6 inhibitor patient selection/sequencing
-
18:07
emerging evidence on the role of cdk4/6 inhibitors in early bc
-
3:19
cdk4/6 inhibitors: changing the treatment landscape
-
31:32
atlas and cdk4/6 inhibitor trials presented by dr. john smith ii, compass oncology
-
13:05
expert perspectives: cdk 4/6 inhibitor therapy for er metastatic breast cancer
-
2:27
understanding abemaciclib: a new cdk4/6 inhibitor
-
2:58
patients’ perspectives on cdk4/6 inhibitors